Cyclo(phenylalanine-proline) induces DNA damage in mammalian cells via reactive oxygen species

Kwanghyun Lee, Jae Eun Jeong, In Hwang Kim, Kun-Soo Kim *, Bong-Gun Ju *

Department of Life Science, Sogang University, Seoul, Korea

Received: March 30, 2015; Accepted: August 3, 2015

Abstract

Cyclo(phenylalanine-proline) is produced by various organisms such as animals, plants, bacteria and fungi. It has diverse biological functions including anti-fungal activity, anti-bacterial activity and molecular signalling. However, a few studies have demonstrated the effect of cyclo(phenylalanine-proline) on the mammalian cellular processes, such as cell growth and apoptosis. In this study, we investigated whether cyclo(phenylalanine-proline) affects cellular responses associated with DNA damage in mammalian cells. We found that treatment of 1 mM cyclo(phenylalanine-proline) induces phosphorylation of H2AX (S139) through ATM-CHK2 activation as well as DNA double strand breaks. Gene expression analysis revealed that a subset of genes related to regulation of reactive oxygen species (ROS) scavenging and production is suppressed by the cyclo(phenylalanine-proline) treatment. We also found that cyclo(phenylalanine-proline) treatment induces perturbation of the mitochondrial membrane, resulting in increased ROS, especially superoxide, production. Collectively, our study suggests that cyclo(phenylalanine-proline) treatment induces DNA damage via elevation of ROS in mammalian cells. Our findings may help explain the mechanism underlying the bacterial infection-induced activation of DNA damage response in host mammalian cells.

Keywords: cyclo(phenylalanine-proline) ● DNA damage ● reactive oxygen species ● cyclo dipeptide ● comet assay

Introduction

Naturally abundant cyclic dipeptides (2,5-diketopiperazines, CDPs) are produced by bacteria, fungi, plants and animals [1, 2]. CDPs have been shown to be generated by large multimodular nonribosomal peptide synthetases. However, nonribosomal peptide synthetases-independent cyclic peptide biosynthesis by tRNA-dependent cyclodipeptide synthases is also found in some bacteria [3, 4]. CDPs have diverse biological functions such as anti-fungal, anti-bacterial, anti-viral, anti-tumour, cell signalling, virulent factor and immunosuppressive activities [5-11].

Cyclo(phenylalanine-proline) (cFP) is produced by various bacteria such as Lactobacillus reuteri, Streptomyces sp. AMLK-335, Vibrio vulnificus, V. cholera, Pseudomonas aeruginosa and P. putida [6, 7, 12-15]. A number of studies have been conducted to investigate the biological function of cFP. For example, cFP demonstrated an antibacterial function against diverse bacteria such as Escherichia coli and P. aeruginosa [16]. In addition, cFP from the L. plantarum strain was shown to be anti-fungal [17]. In some bacteria, cFP functions as a quorum-signal molecule. cFP from V. vulnificus was shown to induce the ampU gene, which is important for the pathogenicity of V. vulnificus [6]. In V. cholera, cFP attenuates the production of the cholera toxins by activating the expression of the regulatory gene leuO [7]. The L. reuteri RC-14 also produces cFP, which inhibits the quorum-sensing system in staphylococci, leading to repression of the expression of staphylococcal exotoxin toxic shock syndrome toxin-1 in the human vagina [15]. CDPs including cFP from P. aeruginosa promote growth of Arabidopsis thaliana seedlings through activation of auxin-regulated gene expression [18]. These results indicate that cFP may be an evolutionally conserved signalling molecule among bacteria or between prokaryotes and eukaryotes.

A few studies have reported the biological effects of cFP on mammalian cell differentiation and metabolism. When HT-29 colon adenocarcinoma cells are treated with cFP, cells are differentiated, most likely because of alternation of gene expression via increased cAMP response element-binding protein (CREB) phosphorylation and histone acetylation [5]. High concentration of cFP induces cell growth arrest and apoptosis through caspase-3 activation and Poly ADP ribose polymerase (PARP) cleavage in HT-29 colon cancer cells [19, 20]. Interestingly, treatment of 10 μM cFP isolated from Strepto-
myces sp. AMLK-335 specifically inhibits DNA topoisomerase I activity, with reduced DNA relaxation in in vitro assay, indicating that cFP may be used as an anti-tumour agent [14]. In the present study, we investigated the function of cFP in DNA damage response in mammalian cells. Our results indicate that cFP induces DNA damage such as DNA double strand break (DSB) through elevation of ROS by suppression of a subset of genes related to ROS metabolism as well as perturbation of the mitochondrial membrane in mammalian cells.

**Materials and methods**

**Cell lines and chemicals**

INT-407 cell, U2OS cells and Huh7 cells were maintained in DMEM supplemented with 10% foetal bovine serum and antibiotics. Linear phenylalanine-proline peptides (P6258; Sigma-Aldrich, St. Louis, MO, USA) and cyclo(phenylalanine-proline) peptide (G4720; Bachem, Bubendorf, Switzerland) were dissolved in DMEM containing 10% FBS and antibiotics. Cells were incubated with the anti-phospho H2AX (S139) (05-636; Millipore), anti-phospho ATM (S1981) (ab1888; Abcam), anti-phospho ATR (S428) (sc109912; Santa Cruz Biotechnology), anti-phospho CHK2 (T68) (04-1471; Millipore) and anti-β-actin (YF-MA-10008; AElfrontier, Seoul, Korea) antibodies by standard procedures. Detection of released cytochrome c in the cytoplasm was performed according to previous procedure [21]. Briefly, cells were suspended with cold iBeCells-1 buffer [225 mM mannitol, 75 mM sucrose, 0.1 mM EGTA, 30 mM Tris-HCl (pH 7.4)] and immediately pipetted on to slide glass. The slide glasses were placed at 4°C for over-night. After clearing by centrifugation, Western blotting was carried out using anti-cytochrome c (ab13575; Abcam) antibody. Western blots were analysed quantitatively using the ImageJ software (NIH, Bethesda, MD, USA). The band intensity was normalized against β-actin and band intensity of control considered as 1.

**Neutral comet assay**

Cells were combined with 1% low melting agarose at a ratio of 1:10 (v/v) and immediately pipetted on to slide glass. The slide glasses were placed at 4°C for 30 min. and immersed in cold lysis solution (2% sarkosyl, 0.5 M EDTA, 0.5 mg/ml proteinase K, pH 8.0) at 4°C for overnight. After slide glass was washed with 1 x Tris Borate EDTA (TBE) buffer at 4°C for 30 min., electrophoresis was performed for 40 min. at 0.6 V/cm. The slide glass was washed with DIW for 5 min. and 70% Ethanol for 5 min. The slide glass was dried and stained with propidium iodide (P4170, Sigma-Aldrich). DNA damage was analysed by examining at least 50 comets using the Comet Score program (TriTek Corporation, Sunnyucked, VA, USA).

**RNA interference (siRNA)**

INT-407 cells were transfected with siRNA against human ATM (SV 1002; Bioneer, Daejeon, Korea) or control siRNA (sc37007; Santa Cruz Biotechnology) using an XtremaGENE siRNA transfection reagent (Roche, Mannheim, Germany). The efficiency of knock down of specific gene was confirmed with real-time PCR.

**RNA-Seq**

Total RNA was extracted using RNeasy mini kit (Qiagen, Valencia, CA, USA). The quality of the total RNA was evaluated using RNA electo-
pherogram (Experion; Bio-Rad, Hercules, CA, USA) and assessing the mRNA levels were as used for normalization. Oligonucleotides were described in Table S1.

Real-time RT-PCR

First strand cDNA synthesis from total RNA template was performed with PrimeScript II 1st strand cDNA Synthesis Kit (Takara Bio, Otsu, Shiga, Japan). The resulting cDNAs were subjected to real-time PCR with a Stratagene Mx3000P (Agilent Technologies, Santa Clara, CA, USA) using TOP SYBR Green (Enzynomics, Daejeon, Korea). PCR conditions used to amplify all genes were 10 min. at 95°C and 40 cycles of 95°C for 15 sec., 60°C for 40 sec. Expression data were calculated from the cycle threshold (Ct) value using the ΔCt method for quantification. GAPDH mRNA levels were as used for normalization. Oligonucleotides were described in Table S1.

ROS measurement

After cells were harvested with trypsin-EDTA and washed with PBS, cells were stained with 5 μM dichlorofluorescein diacetate (DCFDA; D6883; Sigma-Aldrich) for 90 min. at 37°C or 5 M MitoSox Red (M36008; Molecular Probes, Eugene, OR, USA) for 30 min. at 37°C in the dark. Flow cytometry was performed with flow cytometer (FACSCalibur; BD Bioscience, San Jose, CA, USA) in the FL1 channel for DCFDA or FL3 channel for MitoSox Red. For cell imaging, cells were stained with 5 μM Rhodamine 123 (R8004; Sigma-Aldrich) for 30 min. at 37°C in the dark. Flow cytometry was performed with flow cytometer (FACSCalibur; BD Bioscience, San Jose, CA, USA) in the FL1 channel.

Mitochondria membrane potential measurement

Cells were stained with 5 μM Rhodamine 123 (R8004; Sigma-Aldrich) for 30 min. at 37°C in the dark. Flow cytometry was performed with flow cytometer (FACSCalibur; BD Bioscience, San Jose, CA, USA) in the FL1 channel.

Statistical analyses

All quantitative data are presented as mean ± S.D. for three independent experiments. ANOVA was used for multiple comparisons. Significance values were *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.005.

Results

Induction of DNA damage by cFP treatment in mammalian cells

cFP is produced from bacteria, fungi, plants and animals. It may function as an anti-cancer agent by induction of apoptosis or inhibition of DNA topoisomerase I [5, 14, 19, 20]. To investigate the possibility that cFP treatment can induce DNA damage response in mammalian cells. We chose HeLa derivative INT-407 cell line as in vitro model because it has been used in the studies on DNA damage and pathogenesis of Vibrio sp., which produces cFP [6, 7, 24–31]. We first measured the level of DNA damage with γH2AX foci formation using an anti-phospho H2AX (S139) antibody. We observed cFP-induced accumulation of γH2AX foci in concentration and incubation time-dependent manner (Fig. 1A and Fig. S1). In particular, γH2AX foci formation was detected readily at 48 hrs after 1 mM cFP treatment. In contrast, untreated control (CTR) or linear Phe-Pro dipeptides (FP) did not induce γH2AX foci formation in any tested concentrations or incubation times (Fig. 1A). As a positive control, INT-407 cells were treated with 1 μM doxorubicin (Doxo), a DNA damage-inducing agent. To exclude the cell line specific response to cFP treatment, several mammalian cells including U2OS osteosarcoma and HuH7 hepatoma cells were tested. Although there was some variation in concentration and incubation time for cFP treatment, we consistently observed cFP-induced γH2AX foci formation (Fig. S2). We further confirmed cFP-induced DNA damage by Western blot analysis. While phosphorylation of H2AX (S139) was barely detected in linear FP dipeptides-treated INT-407 cells, increased phosphorylation of H2AX (S139) was observed at 48 hrs after 1 mM cFP treatment (Fig. 1B). To detect the physical DSB in cFP-treated INT-407 cells, a neutral comet assay was performed. As expected, we found a significant increase in DSB in 1 mM cFP-treated cells (Fig. 1C). However, we did not observe increased DSB in linear FP dipeptides-treated cells. Collectively, these results suggest that cFP treatment induces DNA damage such as DSB in mammalian cells.

Activation of DNA damage response in cFP-treated INT-407 cells

DNA damage triggers a cellular signalling pathway that regulates the cell cycle and DNA damage repair through either ATR-CHK1 or ATM-CHK2 activation. Therefore, we next checked ATR and ATM activation in 1 mM cFP-treated INT-407 cells using anti-phospho ATR (S428) and anti-phospho ATM (S1981) antibodies respectively. Western blot analysis revealed that phosphorylation level of ATR (S428) did not change by cFP treatment as compared to untreated control (CTR) or linear Phe-Pro dipeptides (FP) treatment (Fig. 2A). However, we observed increased phosphorylation of ATM (S1981) and CHK2 (T68), indicating that cFP-induced DNA damage response is occurred through the activation of ATM-CHK2 signalling pathway. In addition, we did not observe phosphorylation of ATM and CHK2 in FP dipeptides-treated cells (Fig. 2A). We further confirmed the activation of ATM by co-localization of phos-
phorylated ATM (S1981) with γH2AX foci in 1 mM cFP-treated INT-407 cells (Fig. 2B). We also observed co-localization of the 53BP1 checkpoint protein with γH2AX foci in 1 mM cFP-treated cells (Fig. 2C).

**Requirement of ATM in cFP-induced DNA damage response**

Next, we tested whether cFP-induced DNA damage is dependent on ATM kinase, which functions as a DNA damage sensor and phosphorylates H2AX (S139). We first depleted expression of ATM by siRNA in INT-407 cells, and cells were treated with 1 mM cFP (Fig. 3A). Using ATM-depleted INT-407 cells, the level of DNA damage was determined with γH2AX foci formation after 1 mM cFP treatment for 48 hrs. We found decreased γH2AX foci formation in 1 mM cFP-treated cells as compared to control siRNA-transfected cells (Fig. 3B). We further confirmed a decreased level of H2AX (S139) phosphorylation by Western blot analysis (Fig. 3C). Given that kinase activity of ATM is critical for the DNA damage sensor and H2AX (S139) phosphorylation, we treated INT-407 cells with 1 mM cFP in conjunction with 10 μM ATM inhibitor (KU-55933) or DMSO solvent. As with ATM depletion by siRNA, we found decreased γH2AX foci formation by immunocytochemistry (Fig. 3D) and decreased H2AX phosphorylation (S139) by Western blot analysis (Fig. 3E). Collectively, these results suggest that ATM is required for cFP-induced DNA damage response such as H2AX (S139) phosphorylation.

**Treatment of cFP alters the gene expression related to ROS production and scavenging**

To gain insight into the molecular mechanism underlying cFP-induced DNA damage response in INT-407 cells, RNA-seq was performed with total RNA from 1 mM cFP-treated or -untreated INT-407 cells. A relatively small number of genes (38) were regulated in cFP-treated INT-407 cells (8 up-regulated and 30 down-regulated) as compared to untreated cells. Table 1 shows the top 8 up-regulated and 10 down-regulated genes. When 38 regulated genes were analysed using GO (gene ontology), we found that some of the genes participated in GO including response to hypoxia and oxygen level (Table 1). Interestingly, some of the down-regulated genes such as MT1X, MT2A, ADM, ANGPTL4, CTSS, CYP1A1, PFKFB4, FABP3 and DKK1 are involved in regulation of ROS scavenging and production [32–41]. We confirmed the result from RNA-seq by real-time PCR (Fig. 4). These results imply that cFP may induce DNA damage by suppression of genes related to regulation of ROS scavenging and production in mammalian cells.

**ROS-dependent DNA damage in cFP-treated INT-407 cells**

Because cFP treatment suppresses a set of genes related to regulation of ROS scavenging and production in INT-407 cells, we determined ROS level in cFP-treated cells by flow cytometry. After INT-407 cells were treated with 1 mM cFP for 6, 12, 24, 48, 72 hrs, cells were further incubated with DCFDA for 90 min, and flow cytometry was performed. While we did not detect significant ROS production in untreated or FP dipeptides-treated cells, 1 mM cFP-induced ROS production in an incubation time-dependent manner (Fig. 5A and Fig. 5A, compare the black, blue and red lines). We also found that ROS is produced before DNA damage is occurred, which is demonstrated by phosphorylation of CHK2 (T68), ATM (S1981) and H2AX (S139) (Fig. 5B and Fig. 5B). When cells were co-treated with 1 mM cFP and 0.5 mM N-acetylcysteine (NAC) ROS scavenger, increased ROS production by cFP treatment was abolished (Fig. 5A, compare the red and pink lines). Since cFP-induced ROS production and DNA damage response, we investigated whether NAC treatment attenuates DNA damage response by Western blot analysis. We found decreased DNA damage response, which is demonstrated by decreased phosphorylation of CHK2 (T68) and ATM (S1981; Fig. 5B and Fig. 5B). Immunocytochemical results further confirmed that NAC treatment results in decreased γH2AX foci formation (Fig. 5C). Finally, a neutral comet analysis confirmed that cFP-induced physical DSB formation is attenuated significantly by removal of ROS (Fig. 5D).

Since the mitochondrial respiratory chain is the main source of ROS production and superoxide is predominant ROS in mitochondria [42–45], we used MnTBAP, superoxide dismutase (SOD) mimetic, to reduce level of superoxide in cFP-treated cells [46, 47]. To detect superoxide, MitoSox Red reagent also was used for flow cytometric analysis and cell imaging. MnTBAP treatment efficiently reduced cFP-induced superoxide from mitochondria (Fig. S4A). In addition, MnTBAP attenuated cFP-induced DNA damage response, which is assessed by immunocytochemistry, Western blotting, and neutral comet assay (Fig. S4B–D). By measuring cytochrome C release and
membrane potential, we further tested whether cFP impairs the mitochondria membrane. As expected, cFP treatment induced increased cytochrome C release (Fig. 5E) and disturbance of mitochondria potential (Fig. 5F). These results indicate that cFP may also induce DNA damage via ROS, especially superoxide, production in the mitochondria.
Fig. 3 ATM-mediated DNA damage in cFP-treated INT-407 cells. (A) The transcript of ATM was efficiently depleted by ATM siRNA. The expression of ATM was determined by real-time PCR in control (siCTR) or ATM siRNA (siATM). (B) Representative images demonstrate that depletion of ATM decreases γH2AX foci formation in cFP-treated INT-407 cells. After control or ATM siRNA transfection, cells were incubated with 1 mM cFP for 48 hrs and immunostained with an anti-phospho H2AX (S139) antibody. Untreated cells (CTR) were used as a negative control; scale bar, 10 μm. (C) Depletion of ATM decreases phosphorylation of H2AX (S139) in cFP-treated INT-407 cells. After siRNA transfection, cells were incubated with 1 mM cFP for 48 hrs and lysates were immunoblotted with anti-phospho H2AX (S139) antibody. As controls, INT-407 cells were untreated (CTR) or treated with 1 μM doxorubicin (Doxo). Western blots were analysed quantitatively. (D) Representative images demonstrate that enzyme activity of ATM is required for cFP-induced γH2AX foci formation. After cells were incubated with 1 mM cFP in conjunction with 10 μM ATM inhibitor (KU-55933) or DMSO for 48 hrs, cells were immunostained with anti-phospho H2AX (S139) antibody. Untreated cells (CTR) were used as a negative control; scale bar, 10 μm. (E) After cells were incubated with 1 mM cFP in conjunction with 10 μM ATM inhibitor (KU-55933) or DMSO for 48 hrs, the lysates were immunoblotted with anti-phospho H2AX (S139) antibody. As controls, INT-407 cells were untreated (CTR) or treated with 1 μM doxorubicin (Doxo). Western blots were analysed quantitatively. *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.005.
We next tested whether DNA damage repair is restored after washout of cFP in a cell culture. After INT-407 cells were treated with 1 mM cFP for 48 hrs, cell culture media was changed with new media without cFP and cultured for the indicated times. We found that washout of cFP decreases ROS production in INT-407 cells (Fig. 6A, compare the red and pink lines). In addition, immunocytochemistry clearly showed a decreased number of $\gamma$H2AX foci formation at 24 hrs after washout of cFP (Fig. 6B). Consistently, Western blot analysis indicated decreased phosphorylation of H2AX (S139) after washout of cFP (Fig. 6C). We further examined whether DNA damage repair would restore after washout of cFP by a neutral comet assay. Parallel with the above results, DNA damage was significantly decreased (Fig. 6D). Interestingly, INT-407 cells treated with 1 mM cFP for 120 hrs retained the DNA damage repair capacity (Fig. S5). However, more than 8 mM cFP treatment for 48 hrs failed to restore DNA damage repair, showing decreased survived cells (Fig. S6A).

| Gene   | Reads  | log$_2$ (fold change) | $P$-value | GO pathway                                      |
|--------|--------|-----------------------|-----------|------------------------------------------------|
| RANBP3L | 10.9941 | 2.54324               | 5.00E-05  | Transport                                       |
| COL15A1 | 20.4543 | 2.42053               | 5.00E-05  | Angiogenesis, Blood vessel morphogenesis, Blood vessel development |
| MUC16  | 7.37539 | 2.11018               | 5.00E-05  | Cell adhesion                                   |
| NR4A2  | 7.95682 | 2.07375               | 0.00065   | Response to hypoxia, Response to oxygen levels, Response to inorganic substance |
| RPPH1  | 110.345 | 2.03445               | 0.00085   | Response to stimulus                            |
| ALDH1L2 | 2.03469 | 2.01453               | 0.0008    | Response to drug                                |
| PCL0   | 2.02115 | 1.57126               | 0.0008    | Regulation of hormone levels                    |
| NR4A1  | 46.9685 | 1.36902               | 0.00085   | Response to hypoxia, Response to oxygen levels  |
| MT2A   | 146.666 | –1.61239              | 0.0002    | Response to immune system                       |
| ACS2   | 23.8998 | –1.79115              | 5.00E-05  | Lipid biosynthetic process                      |
| CYR61  | 16.8891 | –1.8206               | 5.00E-05  | Angiogenesis, Blood vessel morphogenesis, Blood vessel development |
| PFKFB4 | 1.99561 | –2.04262              | 0.00045   | Fructose metabolic process                      |
| ALDOC  | 12.4805 | –2.35588              | 5.00E-05  | Response to hypoxia, Response to oxygen levels  |
| CYP1A1 | 2.74474 | –2.41925              | 5.00E-05  | Response to hypoxia, Response to oxygen levels, Isoprenoid metabolic process, Isoprenoid biosynthetic process, Response to inorganic substance, Terpenoid metabolic process, Lipid biosynthetic process |
| CA9    | 2.95148 | –2.65043              | 5.00E-05  | Response to hypoxia, Response to oxygen levels  |
| ADM    | 5.2022  | –2.83732              | 5.00E-05  | Response to hypoxia, Response to oxygen levels, Lipid biosynthetic process |
| MT1X   | 13.2878 | –3.09664              | 5.00E-05  | Response to inorganic substance                 |
| GBP1   | 1.72728 | –3.21058              | 5.00E-05  | Response to immune system                       |

Table 1 Up- or down-regulated genes in cFP-treated INT-407 cells

© 2015 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
but slowly accumulated within 48 hrs after 1 mM cFP treatment, indicating that cFP may alter cell metabolism rather than inducing DSB directly. In addition, RNA-seq analysis demonstrated that cFP treatment may induce DNA damage via elevated ROS production and/or decreased ROS scavenging. Most of the down-regulated genes such as MT1X, MT2A, ADM, CTSS, PFKFB4, FABP3 and DKK1 are involved in response to hypoxia and oxygen level and DNA damage. Among them, it has been reported that metallothioneins such as MT1X and MT2A protect against ROS toxicity by ROS scavenging activity in plant and animal cells [52–56]. Adrenomedullin (ADM) also has antioxidant activity in angiotensin II-induced ROS generation in vascular smooth muscle cells [57]. This effect may be because of the increased activities of glutathione peroxidase and reductase and maintained total and active reduced thioredoxin levels [34]. In addition, when Cathepsin S (CTSS) was inhibited, autophagy and intracellular ROS were induced in HONE1 nasopharyngeal carcinoma cells [36]. Depletion of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) resulted in a significant decrease in the levels of Dihydroroticotinamid-deaminucleotide phosphate (NADPH) that maintain cellular stores of reduced glutathione antioxidant, leading to increased accumulation of ROS in prostate cancer cells [38]. Furthermore, depletion of Fatty acid binding protein 3 (FABP3) enhanced ROS production in P19 embryonic carcinoma cells [39]. Depletion of Dickkopf WNT signaling pathway inhibitor 1 (DKK1), an antagonist of Wnt/β-catenin signalling, induced intracellular ROS because of up-regulation of ROMO1 (ROS modulator 1) expression in A549 cells [40]. Although decrease in some genes such as CYP1A1, ANGPTL4 and CCN1 resulted in the reduction of ROS production in specific situations [35, 58, 59], we have suggested that 1 mM cFP treatment may increase intracellular ROS production by dysregulation of genes related to ROS scavenging and production. Consistent with RNA-seq results, cFP treatment indeed resulted in increased ROS production. In addition, elevated ROS was observed before DNA damage is occurred by cFP treatment (Fig. 5A and Fig. S3). Accumulating evidence indicates that ROS induces oxidative DNA damage by formation of oxidative DNA base adducts including 8-oxoG, leading to DSB formation [60–62]. Although cFP down-regulated genes related to regulation of ROS scavenging and production in mammalian cells, we further found that cFP treatment triggers mitochondrial perturbation, which results in ROS production. In fact, it has
Fig. 5 ROS-dependent DNA damage in cFP-treated INT-407 cells (A) The level of ROS is elevated by 1 mM cFP treatment in INT-407 cells. However, 1 mM linear FP dipeptides (FP) treatment does not elevate level of ROS. After cells were incubated with 1 mM cFP in conjunction with 0.5 mM N-acetylcysteine (NAC) or H2O for 48 hrs, ROS level was determined by flow cytometry using DCFDA. Untreated cells (CTR) were used as a negative control. (B) ROS scavenger treatment decreases cFP-induced phosphorylation of CHK2 (T68) and ATM (S1981). The lysates were immunoblotted with anti-phospho CHK2 (T68) and anti-phospho ATM (S1981) antibodies respectively. As controls, INT-407 cells were untreated (CTR) or treated with 1 μM doxorubicin (Doxo). Western blots were analysed quantitatively. (C) Representative images demonstrate that ROS scavenger treatment decreases cFP-induced γH2AX foci formation. After cells were incubated with 1 mM cFP in conjunction with 0.5 mM NAC or H2O for 48 hrs, cells were immunostained with anti- phospho H2AX (S139) antibody. Untreated cells (CTR) were used as a negative control; scale bar, 10 μm. (D) ROS scavenger treatment attenuates cFP-induced DNA damage. After cells were incubated with 1 mM cFP in conjunction with 0.5 mM NAC or H2O for 48 hrs, a neutral comet assay was performed. Untreated cells (CTR) were used as a negative control. (E) Increased cytochrome C release in cFP-treated INT-407 cells. The cytoplasmic fraction from 1 mM cFP or linear FP dipeptides-treated INT-407 cells was immunoblotted with an anti-cytochrome C antibody as described in Materials and Methods section. Untreated cells (CTR) were used as a negative control. Western blots were analysed quantitatively. (F) Disturbance of mitochondrial membrane is induced in cFP-treated INT-407 cells. After INT-407 cells were treated with 1 mM cFP or linear FP dipeptides for 48 hrs, cells were stained with 5 μM Rhodamine 123 and flow cytometry was performed. Untreated cells (CTR) were used as a negative control. *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.005.
been known that mitochondrial respiratory chain is the main source of ROS production and superoxides are predominant ROS in mitochondria [42–45]. Consistently, we found that MnTBAP, SOD mimetic, treatment abolishes cFP-induced DNA damage, indicating that superoxide may be the main ROS induced by cFP treatment (Fig. S4). However, we cannot rule out the possible existence of ROS-independent DSB formation by cFP treatment. For example, cFP inactivates the activity of DNA topoisomerase I that relaxes DNA supercoiling during replication and transcription [14]. In the case of the camptothecin DNA topoisomerase I inhibitor, it forms a cleavage complex and prevents the DNA re-ligation step, leading to DNA single strand breaks (SSBs) [63, 64]. This cleavage complex collides with the replication fork during the S phase, resulting in conversion of SSB into DSB [65].
Given that millimolar cFP is produced in many pathogenic bacteria including *V. vulnificus*, and the fact that it plays an important role in regulation of virulence and biofilm formation, which may affect bacteria-host interaction [6, 7, 66], it is tempting to speculate that cFP itself functions as a virulence factor. Several reports have demonstrated that bacterial infections or pathogens induce DSB in host mammalian cells. For example, infection of pathogenic *Escherichia coli* of phylogenetic group B2 expressing a putative hybrid peptide-polyketide colibactin induces DSB and activation of DNA damage response, resulting in cell cycle arrest and eventually host cell death [67]. Similarly, *Mycoplasma pneumoniae* infection induces changes of protein expression related to oxidative stress and ROS production, leading to DSB in A549 cells [68]. In addition, *Chlamydia trachomatis* infection results in ROS production, ERK-dependent DSB formation and malignant transformation [69]. In contrast, *Helicobacter pylori* infection induces ROS-independent and ATM-dependent DSB formation, leading to genomic instability and gastric carcinogenesis, although no virulence factor or DSB inducing factor has been identified [70].

Collectively, we demonstrate that cFP induces elevation of ROS, especially superoxide by perturbation of mitochondria membrane as well as dysregulation of a subset of genes related to ROS scavenging and production. In turn, this event results in DNA damage such as DSB in mammalian cells (Fig. 6E). Our findings may explain the bacterial infection-induced activation of DNA damage response or carcinogenesis in host mammalian cells. However, it is necessary to identify the mechanism underlying cFP uptake, signalling pathway and interacting partners for the clarification of the biological function of cFP. In addition, it is important to develop bacteria that cannot synthesize cFP by destroying responsible genes such as nonribosomal peptide synthetases or tRNA-dependent cyclodipeptide synthases to test our hypothesis.

**Acknowledgements**

We thank other member of the laboratory for valuable discussion and technical helps. This research was supported by National Research Foundation of Korea (NRF) funded by the Ministry of Education (2009-0093822 to BJ) and Ministry of Science, ICT & Future Planning (2011-0018115 to KK).

**Conflicts of interest**

The authors confirm that there are no conflicts of interest.

**Author contribution**

Conceived and designed the experiments: KL KK BJ. Performed the experiments: KL JJ. Analysed the data: KL JJ IK KK BJ. Contributed reagents/materials/analysis tools: KK. Wrote the paper: KK BJ.

**Supporting information**

Additional Supporting Information may be found in the online version of this article:

**Figure S1** Induction of DNA damage in cFP-treated INT 407 cells.

**Figure S2** Induction of DNA damage in 5 or 20 mM cFP-treated U2OS osteosarcoma cells and HuH7 hepatoma cells respectively.

**Figure S3** Incubation time-dependent ROS production and DNA damage in 1 mM cFP-treated INT-407 cells.

**Figure S4** Superoxide-dependent DNA damage in 1 mM cFP-treated INT-407 cells.

**Figure S5** Incubation time-independent restoration of DNA damage repair after removal of cFP.

**Figure S6** Dose-dependent restoration of DNA damage repair after removal of cFP.

**Table S1** Oligonucleotides used in this study for real-time PCR.

**References**

1. **Prasad C.** Bioactive cyclic dipeptides. *Peptides*. 1995; 16: 151–64.
2. **Huang R, Zhou X, Xu T, et al.** Diketopiperazines from marine organisms. *Chem Biodivers*. 2010; 7: 2809–29.
3. **Belin P, Moutiez M, Lautru S, et al.** The nonribosomal synthesis of diketopiperazines in tRNA-dependent cyclodipeptide synthase pathways. *Nat Prod Rep*. 2012; 29: 961–79.
4. **Giessen TW, Marahiel MA.** The tRNA-dependent biosynthesis of modified cyclic dipeptides. *Int J Mol Sci*. 2014; 15: 14610–31.
5. **Graz CJ, Grant GD, Brauns SC, et al.** Cyclic dipeptides in the induction of maturation for cancer therapy. *J Pharm Pharmacol*. 2000; 52: 75–82.
6. **Park DK, Lee KE, Baek CH, et al.** Cyclic (Phe-Pro) modulates the expression of *ompU* in Vibrio spp. *J Bacteriol*. 2006; 188: 2214–21.
7. **Bina XR, Bina JE.** The cyclic dipeptide cyclo (Phe-Pro) inhibits cholera toxin and toxin-coregulated pilus production in O1 El Tor *Vibrio cholerae*. *J Bacteriol*. 2010; 192: 3289–32.
8. **de Carvalho MP, Abraham WR.** Antimicrobial and biofilm inhibiting diketopiperazines. *Curr Med Chem*. 2012; 19: 3564–77.
19. Brauns SC, Grottelli S, Miera A, et al. Cyclo (His-Pro) exerts anti-inflammatory effects by modulating NF-κB and Nrf2 signalling. *Int J Biochem Cell Biol*. 2012; 44: 525–35.

20. Kwak MK, Liu R, Kwon JO, et al. Cyclic dipeptides from lactic acid bacteria inhibit proliferation of the influenza A virus. *J Microbiol*. 2013; 51: 836–43.

21. Kumar SN, Nambisan B, Mohandas C. Purification and identification of two antifungal cyclic dipeptides from Bacillus cereus subsp. thuringiensis associated with a rabbit-dident entomopathogenic nematode especially against Fusarium oxysporum. *J Enzyme Inhib Med Chem*. 2014; 29: 190–7.

22. Holden MT, Ram Chhabra S, de Nys R, et al. Quorum-sensing cross talk: isolation and chemical characterization of cyclic dipeptides from *Pseudomonas aeruginosa* and other gram-negative bacteria. *Mol Microbiol*. 1999; 33: 1254–66.

23. Degrassi G, Aguilar C, Bosco M, et al. Plant growth-promoting *Pseudomonas* putida WCS358 produces and secretes four cyclic dipeptides: cross-talk with quorum sensing bacterial sensors. *Curr Microbiol*. 2002; 45: 250–4.

24. Rhee KH. Inhibition of DNA topoisomerase I by cyclo(L-Pro)-L-L-Phe-L-Pro isolated from Streptomyces sp. AMLK-335. *J Microbial Biotechnol*. 2002; 12: 1013–6.

25. Li J, Wang W, Xu SX, et al. Lactobacillus reuteri-produced cyclic dipeptides quench agr-mediated expression of toxic shock syndrome toxin-1 in staphylococci. *Proc Natl Acad Sci USA*. 2011; 108: 3360–5.

26. Graz M, Hunt A, Jamie H, et al. Antimicrobial activity of selected cyclic dipeptides. *Pharmazie*. 1999; 54: 722–5.

27. Strom K, Sjogren J, Broberg A, et al. Lactobacillus plantarum MILAB 393 produces the antifungal cyclic dipeptides cyclo(L-Pro-L-Pro) and cyclo(L-Pro-L-Pro) from supporting microbial cells. *Appl Environ Microbiol*. 2002; 68: 4322–7.

28. Ortil-Castro R, Diaz-Perez C, Martinez-Trujillo M, et al. Transkingdom signaling based on bacterial cyclo(dipeptide) with auxin activity in plants. *Proc Natl Acad Sci USA*. 2011; 108: 7253–8.

29. Brauns SC, Milne P, Naudé R, et al. Selected cyclic dipeptides inhibit cancer cell growth and induce apoptosis in HT-29 colon cancer cells. *Anticancer Res*. 2004; 24: 1713–9.

30. Brauns SC, Deeatly G, Milne P, et al. Caspase-3 activation and induction of PARP cleavage by cyclic dipeptide cyclo(Phe-Pro) in HT-29 cells. *Anticancer Res*. 2005; 25: 4197–202.

31. Wieckowski MR, Giorgi C, Lebiedzinska M, et al. Isolation of mitochondria-associated membranes and mitochondria from animal tissues and cells. *Nat Protoc*. 2009; 4: 1582–90.

32. Kim D, Pernea G, Trapnell C, et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol*. 2013; 14: R36.

33. Trapnell C, Hendrickson DG, Sauvageau M, et al. Differential analysis of gene regulation at transcript resolution with RNA-seq. *Nat Biotechnol*. 2013; 31: 46–53.

34. Kim SM, Kim JY, Lee S, et al. Adenomederulin protects against hypoxia/reoxygenation-induced cell death by suppression of reactive oxygen species via thioli redox systems. *FEBS Lett*. 2010; 584: 213–8.

35. Zhu P, Tan MJ, Huang RL, et al. Angiopoietin-1-like 4 protein protects the prosurvival intracellular O2(·)-H2O2 ratio and confers anoikis resistance to tumors. *Cancer Cell*. 2011; 19: 401–15.

36. Huang GC, Chen KL, Cheung CH, et al. Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase. *Free Radic Biol Med*. 2013; 65: 1473–86.

37. Uno S, Sakurai K, Nebert DW, et al. Protective role of cytochrome P450 1A1 (CYP1A1) against benzo[a]pyrene-induced toxicity in mouse aorta. *Toxicology*. 2014; 316: 34–42.

38. Ros S, Santos CR, Moco S, et al. Functional metabolic screen identifies 6-phospho-fructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. *Cancer Discov*. 2012; 2: 328–43.

39. Shen YH, Song GX, Liu YQ, et al. Silencing of FABP3 promotes apoptosis and induces mitochonrdion impairment in embryonic carcinoma cells. *J Bioenerg Biomembr*. 2012; 44: 317–23.

40. Kim IG, Kim SY, Kim HA, et al. Disturbance of DKK1 level is partly involved in survival of lung cancer cells via regulation of ROMO1 and γ-radiation sensitivity. *Biochem Biophys Res Commun*. 2014; 443: 49–55.

41. Shou J, Ali-Osman F, Multani AS, et al. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylating damage of DNA. *Oncogene*. 2002; 21: 678–89.

42. LENZ G. Mitochondria and reactive oxygen species. Which role in physiology and pathology? *Adv Exp Med Biol*. 2012; 942: 93–136.

43. Marchi S, Giorgi C, Suski JM, et al. Mitochondria-ros crosstalk in the control of cell death and aging. *J Signal Transduct*. 2012; 2012: 329635.

44. Batander C, Fontaine E, Keriel C, et al. Determination of mitochondrial reactive oxygen species: methodological aspects. *J Cell Mol Med*. 2002; 6: 175–87.

45. Kudin AP, Bimpong-Bula NY, Vielhaber S, et al. Characterization of superoxide-producing sites in isolated brain mitochondria. *J Biol Chem*. 2004; 279: 4127–35.
SN38 and doxorubicin: a brake to apoptosis IKK complex by the topoisomerase poisons
activation of nuclear factor kappaB through the p38MAPK/MK2 pathway for survival after DNA damage.

Metallothionein isoform 2A expression is inducible and protects against ROS-mediated cell death in rotenone-treated HeLa cells.

Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin.

The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing.

Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells.

Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells.

Chlamydia infection promotes host DNA damage and proliferation but impairs the DNA damage response.

Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells.

© 2015 The Authors.

Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.